

The molecular diagnostic application that streamlines the interpretation of complex genomic variants by combining a capture-based target enrichment kit with the analytical performance* and advanced features of the SOPHIA DDM™ platform.

Main Features

The CE-IVD marked SOPHIA GENETICS™ Myeloid Solution covers **30 relevant genes** (10 with complete coding sequences) associated with myelodysplastic syndromes, myeloproliferative neoplasms, and leukemia. Probe design is optimized to guarantee high on-target rate and coverage uniformity even in GC-rich regions. The technical limitations related to the analyses of key biomarkers such as *CEBPA*, *ASXL1*, *CALR* and *FLT3* (including detection of internal tandem duplications) are addressed with this CE-IVD marked solution.

| Gene Panel | Variants Called | Recommendations | Wet Lab |
|--|--|---|--|
| <i>ABL1</i> (4-9), <i>ASXL1</i> (10,12,13), <i>BRAF</i> (15), <i>CALR</i> (9), <i>CBL</i> (8,9), <i>CEBPA</i> (all), <i>CSF3R</i> (all), <i>DNMT3A</i> (all), <i>ETV6</i> (all), <i>EZH2</i> (all), <i>FLT3</i> (13-15,20), <i>HRAS</i> (2,3), <i>IDH1</i> (4), <i>IDH2</i> (4), <i>JAK2</i> (all), <i>KIT</i> (2,8-11,13,17,18), <i>KRAS</i> (2,3), <i>MPL</i> (10), <i>NPM1</i> (10,11), <i>NRAS</i> (2,3), <i>PTPN11</i> (3,7-13), <i>RUNX1</i> (all), <i>SETBP1</i> (4), <i>SF3B1</i> (10-16), <i>SRSF2</i> (1), <i>TET2</i> (all), <i>TP53</i> (all), <i>U2AF1</i> (2,6), <i>WT1</i> (6-10), <i>ZRSR2</i> (all) | SNVs Indels CNVs FLT3 ITDs ¹ | Starting material 200 ng DNA Sample type Blood and bone marrow Samples per run / Sequencer (Flow Cell / Ion Chip Kit)³ 24 for Illumina MiSeq® v3 ¹ (2x300bp) 12 for Illumina MiSeq® v2 ¹ (2x250bp) Up to 96 for Illumina NextSeq® 500/550 Mid Output v2 (2x150bp) Up to 96 for Illumina NextSeq® 500/550 High Output v2 (2x150bp) 32 for Ion S5™ using Ion 540™ chip | Day 1: Library Preparation Day 2: Capture and Sequencing Total library preparation time: 2 days |

¹The CE-IVD mark only applies to Illumina MiSeq® using v3 chemistry.

Analytical Performance*

The SOPHIA DDM™ platform analyzes complex NGS data by detecting, annotating and pre-classifying genomic alterations in the genes of this panel. The platform reaches clinical-grade performance¹.

Analysis time² from FASTQ: from 4 hours

| | Observed (%) | Lower 95% CI |
|---------------------------------|--------------|--------------|
| Sensitivity | 99.85 | 96.78 |
| Specificity | 99.99 | 99.98 |
| Accuracy | 99.99 | 99.98 |
| Precision | 99.27 | 96.78 |
| Repeatability | 98.69 | 98.66 |
| Reproducibility | 99.30 | 99.27 |
| Average on-target rate | 87.41 | |
| Coverage uniformity | 99.88 | |
| Mean % of target region > 1000x | > 99 | |
| Limit of detection | 2.5 | |

¹Performance values are based on SNVs and Indels in 237 samples processed on Illumina MiSeq®. The detection of CNVs is not a part of the CE-IVD claim.

One Simple Intuitive Platform: Beyond Analytics

Accelerated assessment and reporting of genomic variants

The platform helps users to immediately focus on relevant genomic alterations. Several features facilitate their interpretation process:

- Hotspot screening
- Algorithm-supported variant pre-classification
- Fully customizable filters
- Comprehensive report

Confident decision-making

The SOPHIA DDM™ platform integrates the OncoPortal™. This feature provides the latest scientific evidence on the actionability and significance of each genomic alteration to support informed decision-making for research purpose.

Access to the SOPHIA GENETICS community

Through the SOPHIA DDM™ platform genomics experts from >750 healthcare institutions interpret their findings and flag the pathogenicity level of variants. This highly valuable information enriches the variant knowledge base and is safely shared among the members of the community, supporting their decision-making process for research purposes.

1. Internal tandem duplications
2. Varies depending on the number of genes, samples multiplexed and server load.
3. Sequencing recommendations and specifications for other sequencing kits and instruments are available upon request.

Somatic gene variant annotations and related content have been powered by, without limitation, The Jackson Laboratory Clinical Knowledgebase (JAX-CKB™). All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

This CE IVD-marked product is For In Vitro Diagnostic Use in Europe, Turkey and Israel markets. This product has not been cleared and approved by the U.S. FDA and may not be approved in some countries/regions. Please contact SOPHIA GENETICS local Sales representatives to obtain the appropriate product information for your country of residence.